Description
Tesamorelin 10mg — FDA-approved GHRH analogue for GH research in Australia. University-verified ≥99% purity. Same-day Sydney dispatch.
Tesamorelin is a synthetic 44-amino acid GHRH analogue with a trans-3-hexenoic acid modification at the N-terminus. FDA-approved as Egrifta, it’s one of few peptides in this class with full regulatory approval, providing extensive clinical data.
What the Research Shows
Research has examined Tesamorelin’s effects on GH secretion and body composition, particularly visceral adipose tissue. The N-terminal modification enhances stability while maintaining GHRH receptor binding affinity.
Clinical trials document its effects on trunk fat, IGF-1 levels, and lipid parameters. Published data provides well-characterised pharmacokinetics, dosing relationships, and safety profiles for research design.
Why Australian Researchers Choose Purpose Labs
Every batch is tested at a leading Australian university — HPLC and mass spectrometry confirm ≥99% purity. No generic overseas certificates.
→ Full Tesamorelin Research Guide
Purity: ≥99% (HPLC)
Form: Lyophilised powder
Molecular Weight: 5135.89 Da
CAS: 218949-48-5
Sequence: 44 amino acids (modified GHRH)
Research: PubMed
▸ Australian university verified
▸ ≥99% purity guaranteed
▸ Same-day dispatch from Sydney
▸ Research-grade lyophilised powder
Related Research and Resources
For research use only. Not for human consumption.
